Kd019 (tesevatinib) (DrugBank: Tesevatinib)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
67 | Polycystic kidney disease | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01559363 (ClinicalTrials.gov) | September 2012 | 9/3/2012 | A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD | A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Polycystic Kidney, Autosomal Dominant | Drug: KD019 (tesevatinib) | Kadmon Corporation, LLC | NULL | Completed | 22 Years | 62 Years | All | 74 | Phase 1;Phase 2 | United States |